74331-99-0Relevant articles and documents
Enzyme-MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy
Lian, Xizhen,Huang, Yanyan,Zhu, Yuanyuan,Fang, Yu,Zhao, Rui,Joseph, Elizabeth,Li, Jialuo,Pellois, Jean-Philippe,Zhou, Hong-Cai
, p. 5725 - 5730 (2018)
Prodrug activation, by exogenously administered enzymes, for cancer therapy is an approach to achieve better selectivity and less systemic toxicity than conventional chemotherapy. However, the short half-lives of the activating enzymes in the bloodstream has limited its success. Demonstrated here is that a tyrosinase-MOF nanoreactor activates the prodrug paracetamol in cancer cells in a long-lasting manner. By generating reactive oxygen species (ROS) and depleting glutathione (GSH), the product of the enzymatic conversion of paracetamol is toxic to drug-resistant cancer cells. Tyrosinase-MOF nanoreactors cause significant cell death in the presence of paracetamol for up to three days after being internalized by cells, while free enzymes totally lose activity in a few hours. Thus, enzyme-MOF nanocomposites are envisioned to be novel persistent platforms for various biomedical applications.